Urolift Pre-SBRT for Reduced Urinary Toxicity in Patients With BPH and Prostate Cancer.
NCT05148156
This study is recruiting at 1 US site in 1 state, according to its ClinicalTrials.gov record last updated .
Summary
Many patients may face long-term urinary side effects following stereotactic body radiation therapy (SBRT), including increased urinary frequency, dysuria, and nocturia. The investigator hypothesizes that Urolift, which represents a novel minimally invasive therapy, may reduce acute and long-term urinary toxicity and side effects of radiation therapy (SBRT).
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Benign Prostatic Hyperplasia
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Not applicable
- Ages
- 50 to 99 years
- Sex
- Male
- Healthy volunteers
- Accepted
- Sponsor
- Northwell Health
- Last updated on ClinicalTrials.gov
- September 29, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
New York · 1
- Northwell Health · Syosset, NY
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.